DEVELOPMENT OF A DIAGNOSTIC TEST SYSTEM FOR EARLY NON-INVASIVE DETECTION OF PROSTATE CANCER BASED ON PCA3 MRNA LEVELS IN URINE SEDIMENT USING QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (QRT-PCR)

Cover Page


Cite item

Full Text

Abstract

The wide introduction of prostatic specific antigen (PSA) determination into clinical practice has resulted in a larger number of prostate biopsies, while the lower age threshold for PSA has led to a larger number of unnecessary prostate biopsies. Hence, there is a need for new biomarkers that can detect prostate cancer. РCА3 is a noncoding messenger ribonucleic acid (mRNA) that is expressed exclusively in prostate cells.  The aim of the study  has been to develop a diagnostic test system for early non-invasive detection of prostate cancer based on PCA3 mRNA levels in urine sediment using quantitative reverse transcription polymerase chain reaction (qRT-PCR). As part of the study, a laboratory diagnostic test system prototype has been designed, an application methodology has been developed and specificity and sensitivity data of the method has been assessed. The diagnostic system has demonstrated its ability to detect significantly elevated levels of PCA 3/ KLK 3 in samples from prostate cancer (PCa) patients compared with those from healthy men. The findings have shown relatively high diagnostic sensitivity, specificity and negative-predictive values for an early non-invasive screening of prostate cancer

About the authors

K. A. Pavlov

Serbsky National Research Center, Moscow, Russian Federation

Author for correspondence.
Email: pkanew@mail.ru
PhD , Senior Research Worker, Department of Fundamental and Applied Neurobiology , V.P. Serbskii State Research Center for Social and Forensic Psychiatry Address: 119991, Moscow, Kropotkin lane 23; tel.: (901) 533-7790 Russian Federation

A. N. Shkoporov

N.I. Pirogov Russian National Research Medical University, Moscow, Russian Federation

Email: a.shkoporov@gmail.com
PhD , Senior Research Worker, Laboratory of Microbiology and Biosafety, N.I. Pirogov Russian National Research Medical University Address: 117997, Moscow, Ostrovityanova St., 1; tel.: (495) 434-16-77 Russian Federation

E. V. Khokhlova

N.I. Pirogov Russian National Research Medical University, Moscow, Russian Federation

Email: ekat.khokhlova@gmail.com
PhD, Research Worker, Laboratory of Microbiology and Biosafety, N.I. Pirogov Russian National Research Medical University Address: 117997, Moscow, Ostrovityanova St., 1; tel.: (495) 434-16-77, fax: (495) 434-17-66 Russian Federation

A. A. Korchagina

N.I. Pirogov Russian National Research Medical University, Moscow, Russian Federation

Email: avilis1@yandex.ru
Ph.D student, Department of Medical Nanobiotechnologies, N. I. Pirogov Russian National Research Medical University Address: 117997, Moscow, Ostrovityanova St., 1; tel.: (495) 434-13-01 Russian Federation

A. V. Sidorenkov

A.I. Evdokimov Moscow State Medical Stomatological University, Moscow, Russian Federation

Email: avsid-v@mail.ru
Urologist, Ph.D student, Department of Urology, A.I. Eudukimov Moscow State University of Medicine and Dentistry Address: 127006, Moscow, Dolgorukovskaya St., 4; tel.: (499) 978-01-21 Russian Federation

M. E. Grigor'ev

N.I. Pirogov Russian National Research Medical University, Moscow, Russian Federation

Email: drgrigoriev@mail.ru
PhD, Professor, Department of Urology, N. I. Pirogov Russian National Research Medical University Address: 117997, Moscow, Ostrovityanova St., 1; tel.: (495) 434-33-98 Russian Federation

D. Yu. Pushkar'

A.I. Evdokimov Moscow State Medical Stomatological University, Moscow, Russian Federation

Email: pkanew@mail.ru
PhD, Professor, Head of the Department of Urology, A.I. Eudukimov Moscow State University of Medicine and Dentistry, Honored Doctor of Russian Federation Address: 127006, Moscow, Dolgorukovskaya St., 4; tel.: (499) 978-01-21 Russian Federation

V. P. Chekhonin

Serbsky National Research Center, Moscow, Russian Federation

Email: chekhoninnew@yandex.ru
Head of the Department of Medical Nanobiotechnologies, N. I. Pirogov Russian National Research Medical University Address: 117997, Moscow, Ostrovityanova St., 1; tel.: (495) 434-04-56 Russian Federation

References

  1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Ann. Oncol. 2007; 18: 581–592.
  2. Kok J.B., Verhaegh G.W., Roelofs R.W., Hessels D., Kiemeney L.A., Aalders T.W., Swinkels D.W., Schalken J.A. Cancer Res. 2002; 62: 2695–2698.
  3. Bryzgunova O.E., Vlasov V.V., Laktionov P.P. Vopr. biomed. khim. = Issues of biomedicine and chemistry. 2007; 1(3): 177–184.
  4. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., Smit F.P., Karthaus H.F., Schalken J.A., Debruyne F.M., Ru N., Isaacs W.B. Cancer Res. 1999; 59 (23): 5975–5979.
  5. Day J.R., Jost M., Reynolds M.A., Groskopf J., Rittenhouse H. Cancer Lett. 2011; 301: 1–6.
  6. Bourdoumis A., Papatsoris A.G., Chrisofos M., Efstathiou E., Skolarikos A., Deliveliotis C. Int. Braz. J. Urol. 2010; 36 (6): 665–668.
  7. van Gils M.P., Hessels D., van Hooij O., Jannink S.A., Peelen W.P., Hanssen S.L., Witjes J.A., Cornel E.B., Karthaus H.F., Smits G.A., Dijkman G.A., Mulders P.F., Schalken J.A. Clin. Cancer Res. 2007; 13 (3): 939–943.
  8. Fradet Y., Saad F., Aprikian A., Dessureault J., Elhilali M., Trudel C., Mâsse B., Piché L., Chypre C. Urology. 2004; 64 (2): 311–315.
  9. Tinzl M., Marberger M., Horvath S., Chypre C. Eur. Urol. 2004; 46 (2): 182–186.
  10. Hessels D., Schalken J.A. Nat. Rev. Urol. 2009; 6 (5): 255–261.
  11. Brawer M.K., Chetner M.P., Beatie J., Buchner D.M., Vessella R.L., Lange P.H. J. Urol. 1992; 147(3 Pt. 2): 841–845.
  12. Roobol M.J., Schröder F.H., van Leeuwen P., Wolters T., van den Bergh R.C., van Leenders G.J., Hessels D. Eur. Urol. 2010; 58 (4): 475–481.
  13. Wang R., Chinnaiyan A.M., Dunn R.L., Wojno K.J., Wei J.T. Cancer. 2009; 115 (17): 3879–3886.

Copyright (c) 1970 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies